Cardiac Biomarkers Testing Devices - Market Insights, Competitive Landscape and Market Forecast-2026
This report can be delivered to the clients within 7-10 Business Days
Cardiac Biomarkers Testing Market By Product Type (Instruments And Reagents & Kits), By Biomarker Type (Troponin, Creatine Kinase-Mb, B-Type Natriuretic Peptide, Myoglobin, And Others]), By Application (Acute Coronary Syndrome, Congestive Heart Failure, Myocardial Infarction, And Others) And By End User (Hospitals, Pathology Labs, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to the rising geriatric population and increasing need for early disease diagnosis
Global Cardiac Biomarkers Testing Market was valued at USD 3.25 billion in 2020, growing at a CAGR of 7.76% during the forecast period from 2021 to 2026 to reach USD 5.07 billion by 2026. Factors such as the increasing prevalence of cardiovascular diseases, the growing need for early diseases diagnosis, rising aging population, and the advancement in research in identifying novel clinically-relevant cardiac biomarkers are stimulating the growth of the cardiac biomarker testing market positively.
Cardiac Biomarkers Testing Market Dynamics:
As per the data provided by the World Health Organization (2021), cardiovascular diseases (CVDs) are the leading cause of death across the globe, accounting for an estimated 17.9 million lives each year. Some of CVDs include myocardial infarction, congestive heart failure, acute coronary syndrome, and other conditions. Furthermore, the same data by the WHO presented that over four out of five CVD deaths list strokes and heart attacks as the main cause, and one-third of these deaths are said to occur prematurely in people below 70 years of age. The data also states that more than three quarters of CVD deaths take place in low- and middle-income countries.
According to the data provided by the European Society for Cardiology (ESC) (2021), each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. They represent about 45% of all deaths in Europe and 37% in the European Union.
As per a study published by Groenwegen et al in 2020 titled “Epidemiology of Heart Failure”, it has been estimated that about 64.3 million people across the globe are living with heart failure.
It has been observed that the current diagnostic and triage systems based on clinical history and electrocardiograms are insufficient in the timely diagnosis of the cardiovascular diseases. They may result in some patients being misdiagnosed and being administered inappropriate treatment, care, and investigations. In some patients, the diagnosis is delayed resulting in the late administration (or no administration) of essential early treatment.
Therefore, the need for an early diagnosis of cardiovascular diseases is fuelling the demand for cardiac biomarker testing.
A biomarker is defined as “a characteristic that is objectively measured and quantified as an indicator of normal biological processes, pathogenic processes or pharmacological response to a therapeutic intervention.” Several cardiac markers have been used in the diagnosis and management of cardiovascular (CV) diseases. Cardiac biomarkers are of great importance in the timely, accurate diagnosis and management of cardiovascular disease as well as improving the prognosis of the disease for the patient. Diagnosis in the golden period is of utmost importance to institute therapy at the earliest and possibly reverse the myocardial damage. Cardiac biomarkers are also a powerful tool for triaging.
However, the lack of sensitivity and specificity to cardiac muscle necrosis continues to be the need to look for newer specific molecules, limited understanding of the biochemistry of the biomarkers, and challenges in sample collection and obtaining results may restrain the growth of the cardiac biomarker testing market during the forecast period.
Cardiac Biomarker Testing Market Segment Analysis:
Cardiac Biomarker Testing market by Product Type (Instruments And Reagents & Kits), by Biomarker Type (Troponin, Creatine Kinase-MB, Natriuretic Peptide, Myoglobin, and Others]), by Application (Acute Coronary Syndrome, Congestive Heart Failure, Myocardial Infarction, and Others) by End User (Hospitals, Pathology Labs, And Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the biomarker type segment of the cardiac biomarker testing devices market, the troponin category of cardiac biomarkers is predicted to account for the largest market revenue share. This can be ascribed to the fact that it is considered as the best cardiac biomarker among all other cardiac biomarker types. This protein is by far the most commonly used biomarker and has highest known sensitivity.
Troponin enters the bloodstream soon after a heart attack and remains in the bloodstream for longer period as compared to other biomarkers. There are two forms of troponin that may be measured- troponin T and troponin I. Troponin I is considered to be highly specific to the heart and stays higher longer than creatinine kinase-MB. The latest guidelines by the American Heart Association (AHA) mention this biomarker to be the best biomarker for finding a heart attack.
Furthermore, in some patients the electrocardiographic evidence of myocardial infraction remains unclear; in such cases, troponin cardiac biomarkers are extensively used.
North America is expected to dominate the Overall Cardiac Biomarkers Testing Market:
Among all the regions, North America is expected to amass the largest share in cardiac biomarker testing market. The growing prevalence of cardiovascular diseases, better healthcare facilities coupled with the presence of major market players as well as higher investment in the research and development activities in the region are predicted to be the major influencing factors in driving the overall growth of the cardiac biomarker testing market over the forecast period.
In North America, the US is expected to account for the largest share in of the North American Cardiac Biomarker Testing market. This can be attributed to the increasing cases of heart diseases. As per the facts provided by the Centers for Disease Prevention and Control (CDC) for the year 2021, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States where about 655,000 Americans die from heart disease each year.
In addition to the above numbers, the data provided by the American Heart Association for the year 2018, the chronic heart disease remains the leading cause of death in the US. The data sheet indicated that in 2018, chronic heart diseases accounted for approximately 13% of deaths in the US causing 365,744 deaths.
Furthermore, as per the data provided by the Canadian Institute for Health Information, in 2020, about 2.4 million Canadians suffered from heart disease and it is considered as second leading cause of death in the country.
Heart diseases in an umbrella term which encompasses numerous indications such as acute coronary syndrome, atherosclerosis, congestive heart failure among others. As per the information provided by the Centers for Disease Control and Prevention (2021), some of the key risk factors associated with heart diseases are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors. Therefore, the presence of large patient population suffering from heart diseases is one of the major factors contributing in the North American cardiac biomarker testing market growth.
Moreover, the large presence of key market players as well as the launch of new products in the region as a reason of extensive R&D activities also provide favorable conditions for the growth of the North American cardiac biomarker testing market.
Cardiac Biomarkers Testing Devices Market Key Players:
Some of the key market players operating in the cardiac biomarker testing market includes Beckman Coulter, Inc, Siemens Healthcare GmbH, Abbott, bioMйrieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc, Bio-Rad Laboratories Inc, Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, Lepu Medical Technology (Beijing) Co. Ltd., Biosynex and others.
Recent Developmental Activities in Cardiac Biomarkers Testing Market:
In April 2021, Roche announced the series of five new intended uses for two key cardiac biomarkers using the Elecsys® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP).
In 2019, Roche Diagnostics launched the VITROS high-sensitivity Troponin I assay
Key Takeaways from the Cardiac Biomarkers Testing Market Report Study
Market size analysis for cardiac biomarker testing market size (2020), and market forecast for 5 years (2021-2026)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the cardiac biomarker testing market.
Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
Key companies dominating the global cardiac biomarker testing market.
Various opportunities available for the other competitor in the cardiac biomarker testing market space.
What are the top performing segments in 2020? How these segments will perform in 2026.
Which is the top-performing regions and countries in the current cardiac biomarker testing market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for cardiac biomarker testing market growth in the coming future?
Target Audience who can be benefited from this Cardiac Biomarker Testing Market Report Study
Cardiac biomarkers testing devices products providers
Research organizations and consulting companies
Cardiac biomarkers testing devices -related organization, association, forum, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in cardiac biomarker testing
Various End-users who want to know more about the cardiac biomarker testing market and latest technological developments in the cardiac biomarker testing market.
Frequently Asked Questions for Cardiac Biomarker Testing Market:
1. What is a cardiac biomarker testing device?
Cardiac biomarkers are protein molecules that are released into the blood after heart damage or heart-stress. These biomarkers act as a potential tool in the detection and diagnosis of various cardiovascular diseases.
2. What is the market for Global Cardiac Biomarker Testing?
Global Cardiac Biomarkers Testing Market was valued at USD 3.25 billion in 2020, growing at a CAGR of 7.76% during the forecast period from 2021 to 2026 to reach USD 5.07 billion by 2026.
3. What are the drivers for Global Cardiac Biomarker Testing Market?
The major drivers of the global cardiac biomarker testing market growth are the increasing prevalence of cardiovascular diseases, the growing need for early diseases diagnosis, rising aging population, and the advancement in research in identifying novel clinically-relevant cardiac biomarkers.
4. What are the key players operating in Global Cardiac Biomarker Testing Market?
Some of the key market players operating in the cardiac biomarker testing market includes Beckman Coulter, Inc, Siemens Healthcare GmbH, Abbott, bioMйrieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc, Bio-Rad Laboratories Inc, , Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, Lepu Medical Technology (Beijing) Co. Ltd., Biosynex and others.
5. What regions has the highest share in Cardiac Biomarker Testing market?
North America is expected to dominate the overall Cardiac Biomarker Testing market during the forecast period, 2021 to 2026. The accumulation of the highest revenue in the market can be ascribed to the rising prevalence of cardiovascular diseases, increasing focus on research and development activities and the increasing collaborations between key market players in the region.
Cardiac Biomarkers Testing Market By Product Type (Instruments And Reagents & Kits), By Biomarker Type (Troponin, Creatine Kinase-Mb, B-Type Natriuretic Peptide, Myoglobin, And Others]), By Application (Acute Coronary Syndrome, Congestive Heart Failure, Myocardial Infarction, And Others) And By End User (Hospitals, Pathology Labs, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to the rising geriatric population and increasing need for early disease diagnosis
Global Cardiac Biomarkers Testing Market was valued at USD 3.25 billion in 2020, growing at a CAGR of 7.76% during the forecast period from 2021 to 2026 to reach USD 5.07 billion by 2026. Factors such as the increasing prevalence of cardiovascular diseases, the growing need for early diseases diagnosis, rising aging population, and the advancement in research in identifying novel clinically-relevant cardiac biomarkers are stimulating the growth of the cardiac biomarker testing market positively.
Cardiac Biomarkers Testing Market Dynamics:
As per the data provided by the World Health Organization (2021), cardiovascular diseases (CVDs) are the leading cause of death across the globe, accounting for an estimated 17.9 million lives each year. Some of CVDs include myocardial infarction, congestive heart failure, acute coronary syndrome, and other conditions. Furthermore, the same data by the WHO presented that over four out of five CVD deaths list strokes and heart attacks as the main cause, and one-third of these deaths are said to occur prematurely in people below 70 years of age. The data also states that more than three quarters of CVD deaths take place in low- and middle-income countries.
According to the data provided by the European Society for Cardiology (ESC) (2021), each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. They represent about 45% of all deaths in Europe and 37% in the European Union.
As per a study published by Groenwegen et al in 2020 titled “Epidemiology of Heart Failure”, it has been estimated that about 64.3 million people across the globe are living with heart failure.
It has been observed that the current diagnostic and triage systems based on clinical history and electrocardiograms are insufficient in the timely diagnosis of the cardiovascular diseases. They may result in some patients being misdiagnosed and being administered inappropriate treatment, care, and investigations. In some patients, the diagnosis is delayed resulting in the late administration (or no administration) of essential early treatment.
Therefore, the need for an early diagnosis of cardiovascular diseases is fuelling the demand for cardiac biomarker testing.
A biomarker is defined as “a characteristic that is objectively measured and quantified as an indicator of normal biological processes, pathogenic processes or pharmacological response to a therapeutic intervention.” Several cardiac markers have been used in the diagnosis and management of cardiovascular (CV) diseases. Cardiac biomarkers are of great importance in the timely, accurate diagnosis and management of cardiovascular disease as well as improving the prognosis of the disease for the patient. Diagnosis in the golden period is of utmost importance to institute therapy at the earliest and possibly reverse the myocardial damage. Cardiac biomarkers are also a powerful tool for triaging.
However, the lack of sensitivity and specificity to cardiac muscle necrosis continues to be the need to look for newer specific molecules, limited understanding of the biochemistry of the biomarkers, and challenges in sample collection and obtaining results may restrain the growth of the cardiac biomarker testing market during the forecast period.
Cardiac Biomarker Testing Market Segment Analysis:
Cardiac Biomarker Testing market by Product Type (Instruments And Reagents & Kits), by Biomarker Type (Troponin, Creatine Kinase-MB, Natriuretic Peptide, Myoglobin, and Others]), by Application (Acute Coronary Syndrome, Congestive Heart Failure, Myocardial Infarction, and Others) by End User (Hospitals, Pathology Labs, And Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the biomarker type segment of the cardiac biomarker testing devices market, the troponin category of cardiac biomarkers is predicted to account for the largest market revenue share. This can be ascribed to the fact that it is considered as the best cardiac biomarker among all other cardiac biomarker types. This protein is by far the most commonly used biomarker and has highest known sensitivity.
Troponin enters the bloodstream soon after a heart attack and remains in the bloodstream for longer period as compared to other biomarkers. There are two forms of troponin that may be measured- troponin T and troponin I. Troponin I is considered to be highly specific to the heart and stays higher longer than creatinine kinase-MB. The latest guidelines by the American Heart Association (AHA) mention this biomarker to be the best biomarker for finding a heart attack.
Furthermore, in some patients the electrocardiographic evidence of myocardial infraction remains unclear; in such cases, troponin cardiac biomarkers are extensively used.
North America is expected to dominate the Overall Cardiac Biomarkers Testing Market:
Among all the regions, North America is expected to amass the largest share in cardiac biomarker testing market. The growing prevalence of cardiovascular diseases, better healthcare facilities coupled with the presence of major market players as well as higher investment in the research and development activities in the region are predicted to be the major influencing factors in driving the overall growth of the cardiac biomarker testing market over the forecast period.
In North America, the US is expected to account for the largest share in of the North American Cardiac Biomarker Testing market. This can be attributed to the increasing cases of heart diseases. As per the facts provided by the Centers for Disease Prevention and Control (CDC) for the year 2021, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States where about 655,000 Americans die from heart disease each year.
In addition to the above numbers, the data provided by the American Heart Association for the year 2018, the chronic heart disease remains the leading cause of death in the US. The data sheet indicated that in 2018, chronic heart diseases accounted for approximately 13% of deaths in the US causing 365,744 deaths.
Furthermore, as per the data provided by the Canadian Institute for Health Information, in 2020, about 2.4 million Canadians suffered from heart disease and it is considered as second leading cause of death in the country.
Heart diseases in an umbrella term which encompasses numerous indications such as acute coronary syndrome, atherosclerosis, congestive heart failure among others. As per the information provided by the Centers for Disease Control and Prevention (2021), some of the key risk factors associated with heart diseases are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors. Therefore, the presence of large patient population suffering from heart diseases is one of the major factors contributing in the North American cardiac biomarker testing market growth.
Moreover, the large presence of key market players as well as the launch of new products in the region as a reason of extensive R&D activities also provide favorable conditions for the growth of the North American cardiac biomarker testing market.
Cardiac Biomarkers Testing Devices Market Key Players:
Some of the key market players operating in the cardiac biomarker testing market includes Beckman Coulter, Inc, Siemens Healthcare GmbH, Abbott, bioMйrieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc, Bio-Rad Laboratories Inc, Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, Lepu Medical Technology (Beijing) Co. Ltd., Biosynex and others.
Recent Developmental Activities in Cardiac Biomarkers Testing Market:
In April 2021, Roche announced the series of five new intended uses for two key cardiac biomarkers using the Elecsys® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP).
In 2019, Roche Diagnostics launched the VITROS high-sensitivity Troponin I assay
Key Takeaways from the Cardiac Biomarkers Testing Market Report Study
Market size analysis for cardiac biomarker testing market size (2020), and market forecast for 5 years (2021-2026)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the cardiac biomarker testing market.
Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
Key companies dominating the global cardiac biomarker testing market.
Various opportunities available for the other competitor in the cardiac biomarker testing market space.
What are the top performing segments in 2020? How these segments will perform in 2026.
Which is the top-performing regions and countries in the current cardiac biomarker testing market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for cardiac biomarker testing market growth in the coming future?
Target Audience who can be benefited from this Cardiac Biomarker Testing Market Report Study
Cardiac biomarkers testing devices products providers
Research organizations and consulting companies
Cardiac biomarkers testing devices -related organization, association, forum, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in cardiac biomarker testing
Various End-users who want to know more about the cardiac biomarker testing market and latest technological developments in the cardiac biomarker testing market.
Frequently Asked Questions for Cardiac Biomarker Testing Market:
1. What is a cardiac biomarker testing device?
Cardiac biomarkers are protein molecules that are released into the blood after heart damage or heart-stress. These biomarkers act as a potential tool in the detection and diagnosis of various cardiovascular diseases.
2. What is the market for Global Cardiac Biomarker Testing?
Global Cardiac Biomarkers Testing Market was valued at USD 3.25 billion in 2020, growing at a CAGR of 7.76% during the forecast period from 2021 to 2026 to reach USD 5.07 billion by 2026.
3. What are the drivers for Global Cardiac Biomarker Testing Market?
The major drivers of the global cardiac biomarker testing market growth are the increasing prevalence of cardiovascular diseases, the growing need for early diseases diagnosis, rising aging population, and the advancement in research in identifying novel clinically-relevant cardiac biomarkers.
4. What are the key players operating in Global Cardiac Biomarker Testing Market?
Some of the key market players operating in the cardiac biomarker testing market includes Beckman Coulter, Inc, Siemens Healthcare GmbH, Abbott, bioMйrieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc, Bio-Rad Laboratories Inc, , Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, Lepu Medical Technology (Beijing) Co. Ltd., Biosynex and others.
5. What regions has the highest share in Cardiac Biomarker Testing market?
North America is expected to dominate the overall Cardiac Biomarker Testing market during the forecast period, 2021 to 2026. The accumulation of the highest revenue in the market can be ascribed to the rising prevalence of cardiovascular diseases, increasing focus on research and development activities and the increasing collaborations between key market players in the region.
1.CARDIAC BIOMARKER TESTING MARKET REPORT INTRODUCTION
2.CARDIAC BIOMARKER TESTING MARKET EXECUTIVE SUMMARY
2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment
2.4. Financial Benchmarking
3. REGULATORY AND PATENT ANALYSIS
3.1. The United States
3.2. Europe
3.2.1. Germany
3.2.2. France
3.2.3. Italy
3.2.4. Spain
3.2.5. U.K.
3.3. Japan
4. CARDIAC BIOMARKER TESTING MARKET KEY FACTORS ANALYSIS
4.1. Cardiac Biomarker Testing Market Drivers
4.1.1. Rising Prevalence of Cardiovascular Diseases
4.1.2. Increasing Need for Early Disease Diagnosis
4.1.3. Growing Research and Development Activities
4.1.4. Rising Aging Population
4.2. Cardiac Biomarker Testing Market Restraints and Challenges
4.2.1. Limited Understanding of the Biochemistry of Cardiac Biomarkers
4.2.2. Challenges in Sample Collection and Result Time
4.3. Cardiac Biomarker Testing Market Opportunities
4.3.1. Improvement in Understanding of Cardiac Biomarkers
4.3.2. Increasing Point-of-Care Testing with Cardiac Biomarkers
5. CARDIAC BIOMARKER TESTING MARKET PORTER’S FIVE FORCES ANALYSIS
5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry
6. COVID-19 IMPACT ANALYSIS ON CARDIAC BIOMARKER TESTING MARKET
7. CARDIAC BIOMARKER TESTING MARKET LAYOUT
7.1. By Product Type
7.1.1. Instruments
7.1.2. Reagents & Kits
7.2. By Biomarkers Type
7.2.1. Troponin
7.2.2. Creatine Kinase-MB
7.2.3. Natriuretic Peptide
7.2.4. Myoglobin
7.2.5. Others
7.3. By Application
7.3.1. Acute Coronary Syndrome
7.3.2. Congestive Heart Failure
7.3.3. Myocardial Infarction
7.3.4. Others
7.4. By End User
7.4.1. Hospitals
7.4.2. Pathology Labs
7.4.3. Others
7.5. By Geography
7.5.1. North America
7.5.1.1. North America Cardiac Biomarker Testing Market, by Product Type
7.5.1.2. North America Cardiac Biomarker Testing Market, by Biomarker Type
7.5.1.3. North America Cardiac Biomarker Testing Market, by Application
7.5.1.4. North America Cardiac Biomarker Testing Market, by End User
7.5.1.5. North America Cardiac Biomarker Testing Market, by Country
7.5.1.5.1. United States
7.5.1.5.2. Canada
7.5.1.5.3. Mexico
7.5.2. Europe
7.5.2.1. Europe Cardiac Biomarker Testing Market, by Product Type
7.5.2.2. Europe Cardiac Biomarker Testing Market, by Biomarker Type
7.5.2.3. Europe Cardiac Biomarker Testing Market, by Application
7.5.2.4. Europe Cardiac Biomarker Testing Market, by End User
7.5.2.5. Europe Cardiac Biomarker Testing Market, by Country
7.5.2.5.1. France
7.5.2.5.2. Germany
7.5.2.5.3. United Kingdom
7.5.2.5.4. Italy
7.5.2.5.5. Spain
7.5.2.5.6. Russia
7.5.2.5.7. Rest of Europe
7.5.3. Asia-Pacific
7.5.3.1. Asia-Pacific Cardiac Biomarker Testing Market, by Product Type
7.5.3.2. Asia-Pacific Cardiac Biomarker Testing Market, by Biomarker Type
7.5.3.3. Asia-Pacific Cardiac Biomarker Testing Market, by Application
7.5.3.4. Asia-Pacific Cardiac Biomarker Testing Market, by End User
7.5.3.5. Asia-Pacific Cardiac Biomarker Testing Market, by Country
7.5.3.5.1. China
7.5.3.5.2. Japan
7.5.3.5.3. India
7.5.3.5.4. Australia
7.5.3.5.5. South Korea
7.5.3.5.6. Rest of Asia Pacific
7.5.4. Rest of the World (RoW)
7.5.4.1. RoW Cardiac Biomarker Testing Market, by Product Type
7.5.4.2. RoW Cardiac Biomarker Testing Market, by Biomarker Type
7.5.4.3. RoW Cardiac Biomarker Testing Market, by Application
7.5.4.4. RoW Cardiac Biomarker Testing Market, by End User
7.5.4.5. RoW Cardiac Biomarker Testing Market, by Country
7.5.4.5.1. Middle East
7.5.4.5.2. Africa
7.5.4.5.3. South America
8. CARDIAC BIOMARKER TESTING MARKET GLOBAL COMPANY SHARE ANALYSIS – KEY 3-5 COMPANIES
9. CARDIAC BIOMARKER TESTING MARKET COMPANY AND PRODUCT PROFILES
9.1. Beckman Coulter, Inc
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Financial Overview
9.1.4. Product Listing
9.1.5. Entropy
9.2. Siemens Healthcare GmbH
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Financial Overview
9.2.4. Product Listing
9.2.5. Entropy
9.3. Abbott
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Financial Overview
9.3.4. Product Listing
9.3.5. Entropy
9.4. bioMйrieux SA
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Financial Overview
9.4.4. Product Listing
9.4.5. Entropy
9.5. F. Hoffmann-La Roche Ltd
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Financial Overview
9.5.4. Product Listing
9.5.5. Entropy
9.6. Thermo Fischer Scientific Inc
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Financial Overview
9.6.4. Product Listing
9.6.5. Entropy
9.7. Bio-Rad Laboratories Inc
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Financial Overview
9.7.4. Product Listing
9.7.5. Entropy
9.8. Eurolyser Diagnostica GmbH
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Financial Overview
9.8.4. Product Listing
9.8.5. Entropy
9.9. Diagnostic Automation / Cortez Diagnostics, Inc
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Financial Overview
9.9.4. Product Listing
9.9.5. Entropy
9.10. Randox Laboratories Ltd
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Financial Overview
9.10.4. Product Listing
9.10.5. Entropy
9.11. Tosoh Corporation
9.11.1. Company Overview
9.11.2. Company Snapshot
9.11.3. Financial Overview
9.11.4. Product Listing
9.11.5. Entropy
9.12. DIALAB GmbH
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4. Product Listing
9.12.5. Entropy
9.13. CardioGenics Holdings Inc
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4. Product Listing
9.12.5. Entropy
9.14. Lepu Medical Technology (Beijing) Co. Ltd.
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4. Product Listing
9.12.5. Entropy
9.15. Biosynex
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4. Product Listing
9.12.5. Entropy
10. PROJECT APPROACH
10.1. Secondary Sources
10.2. Primary Sources
10.3. Data Triangulation
10.4. Key Expert Opinions
11. KOL VIEWS
12. DELVEINSIGHT CAPABILITIES
13. DISCLAIMER
14. ABOUT DELVEINSIGHT
2.CARDIAC BIOMARKER TESTING MARKET EXECUTIVE SUMMARY
2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment
2.4. Financial Benchmarking
3. REGULATORY AND PATENT ANALYSIS
3.1. The United States
3.2. Europe
3.2.1. Germany
3.2.2. France
3.2.3. Italy
3.2.4. Spain
3.2.5. U.K.
3.3. Japan
4. CARDIAC BIOMARKER TESTING MARKET KEY FACTORS ANALYSIS
4.1. Cardiac Biomarker Testing Market Drivers
4.1.1. Rising Prevalence of Cardiovascular Diseases
4.1.2. Increasing Need for Early Disease Diagnosis
4.1.3. Growing Research and Development Activities
4.1.4. Rising Aging Population
4.2. Cardiac Biomarker Testing Market Restraints and Challenges
4.2.1. Limited Understanding of the Biochemistry of Cardiac Biomarkers
4.2.2. Challenges in Sample Collection and Result Time
4.3. Cardiac Biomarker Testing Market Opportunities
4.3.1. Improvement in Understanding of Cardiac Biomarkers
4.3.2. Increasing Point-of-Care Testing with Cardiac Biomarkers
5. CARDIAC BIOMARKER TESTING MARKET PORTER’S FIVE FORCES ANALYSIS
5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry
6. COVID-19 IMPACT ANALYSIS ON CARDIAC BIOMARKER TESTING MARKET
7. CARDIAC BIOMARKER TESTING MARKET LAYOUT
7.1. By Product Type
7.1.1. Instruments
7.1.2. Reagents & Kits
7.2. By Biomarkers Type
7.2.1. Troponin
7.2.2. Creatine Kinase-MB
7.2.3. Natriuretic Peptide
7.2.4. Myoglobin
7.2.5. Others
7.3. By Application
7.3.1. Acute Coronary Syndrome
7.3.2. Congestive Heart Failure
7.3.3. Myocardial Infarction
7.3.4. Others
7.4. By End User
7.4.1. Hospitals
7.4.2. Pathology Labs
7.4.3. Others
7.5. By Geography
7.5.1. North America
7.5.1.1. North America Cardiac Biomarker Testing Market, by Product Type
7.5.1.2. North America Cardiac Biomarker Testing Market, by Biomarker Type
7.5.1.3. North America Cardiac Biomarker Testing Market, by Application
7.5.1.4. North America Cardiac Biomarker Testing Market, by End User
7.5.1.5. North America Cardiac Biomarker Testing Market, by Country
7.5.1.5.1. United States
7.5.1.5.2. Canada
7.5.1.5.3. Mexico
7.5.2. Europe
7.5.2.1. Europe Cardiac Biomarker Testing Market, by Product Type
7.5.2.2. Europe Cardiac Biomarker Testing Market, by Biomarker Type
7.5.2.3. Europe Cardiac Biomarker Testing Market, by Application
7.5.2.4. Europe Cardiac Biomarker Testing Market, by End User
7.5.2.5. Europe Cardiac Biomarker Testing Market, by Country
7.5.2.5.1. France
7.5.2.5.2. Germany
7.5.2.5.3. United Kingdom
7.5.2.5.4. Italy
7.5.2.5.5. Spain
7.5.2.5.6. Russia
7.5.2.5.7. Rest of Europe
7.5.3. Asia-Pacific
7.5.3.1. Asia-Pacific Cardiac Biomarker Testing Market, by Product Type
7.5.3.2. Asia-Pacific Cardiac Biomarker Testing Market, by Biomarker Type
7.5.3.3. Asia-Pacific Cardiac Biomarker Testing Market, by Application
7.5.3.4. Asia-Pacific Cardiac Biomarker Testing Market, by End User
7.5.3.5. Asia-Pacific Cardiac Biomarker Testing Market, by Country
7.5.3.5.1. China
7.5.3.5.2. Japan
7.5.3.5.3. India
7.5.3.5.4. Australia
7.5.3.5.5. South Korea
7.5.3.5.6. Rest of Asia Pacific
7.5.4. Rest of the World (RoW)
7.5.4.1. RoW Cardiac Biomarker Testing Market, by Product Type
7.5.4.2. RoW Cardiac Biomarker Testing Market, by Biomarker Type
7.5.4.3. RoW Cardiac Biomarker Testing Market, by Application
7.5.4.4. RoW Cardiac Biomarker Testing Market, by End User
7.5.4.5. RoW Cardiac Biomarker Testing Market, by Country
7.5.4.5.1. Middle East
7.5.4.5.2. Africa
7.5.4.5.3. South America
8. CARDIAC BIOMARKER TESTING MARKET GLOBAL COMPANY SHARE ANALYSIS – KEY 3-5 COMPANIES
9. CARDIAC BIOMARKER TESTING MARKET COMPANY AND PRODUCT PROFILES
9.1. Beckman Coulter, Inc
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Financial Overview
9.1.4. Product Listing
9.1.5. Entropy
9.2. Siemens Healthcare GmbH
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Financial Overview
9.2.4. Product Listing
9.2.5. Entropy
9.3. Abbott
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Financial Overview
9.3.4. Product Listing
9.3.5. Entropy
9.4. bioMйrieux SA
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Financial Overview
9.4.4. Product Listing
9.4.5. Entropy
9.5. F. Hoffmann-La Roche Ltd
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Financial Overview
9.5.4. Product Listing
9.5.5. Entropy
9.6. Thermo Fischer Scientific Inc
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Financial Overview
9.6.4. Product Listing
9.6.5. Entropy
9.7. Bio-Rad Laboratories Inc
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Financial Overview
9.7.4. Product Listing
9.7.5. Entropy
9.8. Eurolyser Diagnostica GmbH
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Financial Overview
9.8.4. Product Listing
9.8.5. Entropy
9.9. Diagnostic Automation / Cortez Diagnostics, Inc
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Financial Overview
9.9.4. Product Listing
9.9.5. Entropy
9.10. Randox Laboratories Ltd
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Financial Overview
9.10.4. Product Listing
9.10.5. Entropy
9.11. Tosoh Corporation
9.11.1. Company Overview
9.11.2. Company Snapshot
9.11.3. Financial Overview
9.11.4. Product Listing
9.11.5. Entropy
9.12. DIALAB GmbH
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4. Product Listing
9.12.5. Entropy
9.13. CardioGenics Holdings Inc
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4. Product Listing
9.12.5. Entropy
9.14. Lepu Medical Technology (Beijing) Co. Ltd.
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4. Product Listing
9.12.5. Entropy
9.15. Biosynex
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4. Product Listing
9.12.5. Entropy
10. PROJECT APPROACH
10.1. Secondary Sources
10.2. Primary Sources
10.3. Data Triangulation
10.4. Key Expert Opinions
11. KOL VIEWS
12. DELVEINSIGHT CAPABILITIES
13. DISCLAIMER
14. ABOUT DELVEINSIGHT
